title: Larynx preservation: what is the standard treatment?
abstract: Locally advanced laryngeal and hypo-pharyngeal cancers have a rather poor prognosis. Up until the early 1990s, standard treatment was total laryngectomy, with dramatic functional and social outcome. The introduction of cisplatin based chemotherapy made concurrent chemo-radiotherapy (CCRT) the standard treatment for selected patients, fit for an organ preservation strategy. Over two decades of improvement in nonsurgical management of locally advanced laryngeal cancer is reviewed, including the most recent improvements with the introduction of taxanes and anti-EGFR targeted therapy.
authors.affiliation: Academic Radiation Oncology Department, Centre Oscar Lambret, Service Academique de Radiotherapy, 3 Rue Frédéric Combemale, F-59000 Lille, France.
authors.forename: Samy
authors.initials: S
authors.lastname: Horn
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Lefèbvre
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Horiot
authors.forename: Eric
authors.initials: E
authors.lastname: Lartigau
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D007830:Larynx / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects*; D058990:Molecular Targeted Therapy / Q000379:methods; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D066246:ErbB Receptors